Paper Details

  1. Home
  2. Paper Details

[Osimertinib (Tagrisso<sup>&#174;</sup>): Activity, indication and modality of use in non-small cell lung cancer].

Author: CadranelJacques, CortotAlexis B, Giroux LeprieurEtienne, WislezMarie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Osimertinib is effective for treating lung cancer patients with a specific EGFR mutation (T790M) who have progressed after other treatments. It has a response rate of up to 61% and acceptable side effects.
Paper Details　
Original Abstract of the Article :
The acquisition of a resistance EGFR mutation in exon 20 (T790M) occurs in half of the cases of secondary resistance to EGFR tyrosine kinase inhibitors (TKI), given in first-line treatment in advanced EGFR-mutated non-small cell lung cancers (NSCLC). Osimertinib (AZD9291, Tagrisso<sup>&#174;</sup>) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bulcan.2016.06.007

データ提供：米国国立医学図書館（NLM）

Osimertinib: A New Hope for Treating EGFR-Mutated Lung Cancer

This research explores the complex world of lung cancer treatment, specifically focusing on the development of a new drug called osimertinib. Imagine this research as a journey across a vast desert of cancer research, seeking to find new weapons to fight this deadly disease. The authors examine osimertinib's effectiveness in treating non-small cell lung cancer (NSCLC) that has developed resistance to other EGFR tyrosine kinase inhibitors (TKIs). They emphasize osimertinib's ability to overcome resistance, offering hope to patients who have exhausted other treatment options.

A New Weapon in the Arsenal

This study highlights the potential of osimertinib in combating EGFR-mutated lung cancer. Imagine a warrior finding a new, powerful weapon to fight a formidable foe. The researchers highlight osimertinib's ability to target the T790M mutation, which is responsible for resistance to other EGFR TKIs. This finding suggests a new path forward in the fight against lung cancer, potentially offering a chance for prolonged survival and improved quality of life for patients.

A Promising Path Forward

The researchers underscore the importance of screening for T790M mutations in patients with EGFR-mutated lung cancer. This is crucial for identifying patients who may benefit from osimertinib treatment. Think of it as carefully mapping the desert to identify potential oases of relief. This research provides a valuable tool for clinicians to personalize treatment and provide the best possible care for their patients.

Dr.Camel's Conclusion

Osimertinib presents a beacon of hope in the fight against lung cancer. The research offers a new path forward for treating EGFR-mutated NSCLC, potentially improving outcomes for patients. This research reminds us that even in the face of challenging diseases, the desert of medical research continues to hold the promise of new discoveries and treatments.

Date :
  1. Date Completed 2017-01-30
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

27641462

DOI: Digital Object Identifier

10.1016/j.bulcan.2016.06.007

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.